Identifying health information technology needs of oncologists to facilitate the adoption of genomic medicine: Recommendations from the 2016 American society of clinical oncology omics and precision Oncology workshop

Journal of Clinical Oncology

Volumn 35, Issue 27, 2017, Pages 3153-3159

  Hughes, Kevin S ^a   Ambinder, Edward P ^b   Hess, Gregory P ^d,e   Yu, Peter Paul ^c,f   Bernstam, Elmer V ^g   Routbort, Mark J ^h   Clemenceau, Jean Rene ⁱ   Hamm, John T ^j   Febbo, Phillip G ^k   Domchek, Susan M ^e   Chen, James L ^l   Warner, Jeremy L ^m  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Symphony Health   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f Hartford HealthCare Cancer Institute   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ Angeles Pedregal Hospital   (Mexico)

^j Norton Healthcare   (United States)

^k Genomic Health   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; GENOMICS; HUMAN; KNOWLEDGE; KNOWLEDGE BASE; LABORATORY; MEDICAL INFORMATICS; MEDICAL SOCIETY; NOMENCLATURE; OMICS; ONCOLOGIST; ONCOLOGY; ORGANIZATION; PRIORITY JOURNAL; PROGNOSIS; TIME; WORKSHOP; MOBILE APPLICATION; NEEDS ASSESSMENT; UNITED STATES;

CONGRESSES AS TOPIC; GENOMICS; HUMANS; MEDICAL INFORMATICS; MEDICAL ONCOLOGY; MOBILE APPLICATIONS; NEEDS ASSESSMENT; ONCOLOGISTS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 85029359899     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.1744     Document Type: Article

References (54)

1. Chalmers ZR, Connelly CF, Fabrizio D, et al: Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34, 2017
2. Zehir A, Benayed R, Shah RH, et al: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 10.1038/nm.4333 [epub ahead of print on May 8, 2017]
3. Tannock IF, Hickman JA: Limits to personalized cancer medicine. N Engl J Med 375:1289-1294, 2016
4. Fleck LM: Pharmacogenomics and personalized medicine: Wicked problems, ragged edges and ethical precipices. N Biotechnol 29:757-768, 2012
5. Lawler M, French D, Henderson R, et al: Shooting for the moon or flying too near the sun? Crossing the value Rubicon in precision cancer care. Public Health Genomics 19:132-136, 2016
6. Prasad V: Perspective: The precision-oncology illusion. Nature 537:S63, 2016
7. Ioannidis JPA, Bossuyt PMM: Waste, leaks, and failures in the biomarker pipeline. Clin Chem 63: 963-972, 2017
8. Duffy DJ: Problems, challenges and promises: Perspectives on precision medicine. Brief Bioinform 17:494-504, 2016
9. Clark JW, Chabner BA: Limits to precision cancer medicine. N Engl J Med 376:96, 2017
10. Warner JL: Giving up on precision oncology? Not so fast! Clin Transl Sci 10:128-129, 2017
11. National Center for Biotechnology Information: MeSH: Precision medicine. https://www.ncbi.nlm.nih.gov/mesh/?term=precision+medicine
12. Wikipedia, the free encyclopedia: Omics. https://en.wikipedia.org/w/index.php?title=Omics&oldid= 776067294
13. Hauschild A, Grob J-J, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
14. Shaw AT, Kim D-W, Nakagawa K, et al: Cri-zotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
15. Rubin BP, Schuetze SM, Eary JF, et al: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20: 3586-3591, 2002
16. Stacchiotti S, Pantaleo MA, Negri T, et al: Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). Clin Cancer Res 22:837-846, 2016
17. Jänne PA, Yang JC-H, Kim D-W, et al: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689-1699, 2015
18. Precision Medicine for Me: https://antidote.me/precision-medicine/
19. Kuderer NM, Burton KA, Blau S, et al: Comparison of 2 commercially available next-generation sequencing platforms in oncology. JAMA Oncol 3: 996-998, 2017
20. Balmaña J, Digiovanni L, Gaddam P, et al: Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the Prospective Registry of Multiplex Testing. J Clin Oncol 34:4071-4078, 2016
21. Gradishar W, Johnson K, Brown K, et al: Clinical variant classification: A comparison of public databases and a commercial testing laboratory. Oncologist 22:797-803, 2017
22. Fathiamini S, Johnson AM, Zeng J, et al: Automated identification of molecular effects of drugs (AIMED). J Am Med Inform Assoc 23:758-765, 2016
23. Ziemin-van der Poel S, McCabe NR, Gill HJ, et al: Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 88: 10735-10739, 1991
24. West HJ, Miller G: Genomic testing and precision medicine in cancer care. http://www.medscape.com/slideshow/genomics-and-oncology-report-6008655
25. Warner JL, Jain SK, Levy MA: Integrating cancer genomic data into electronic health records. Genome Med 8:113, 2016
26. Sync4Genes: http://www.sync4genes.org/27. Foundation for the National Institutes of Health: https: //fnih.org/
27. National Institutes of Health: President’s Cancer Panel Reports. https://deainfo.nci.nih.gov/advisory/pcp/annualReports/
28. Mandl KD, Mandel JC, Murphy SN, et al: The SMART platform: Early experience enabling substitutable applications for electronic health records. J Am Med Inform Assoc 19:597-603, 2012
29. Mandel JC, Kreda DA, Mandl KD, et al: SMART on FHIR: A standards-based, interoperable apps platform for electronic health records. J Am Med Inform Assoc 23:899-908, 2016
30. Mandl KD, Mandel JC, Kohane IS: Driving innovation in health systems through an apps-based information economy. Cell Syst 1:8-13, 2015
31. Human Genome Variation Society: Sequence Variation Nomenclature. http://varnomen.hgvs.org
32. Mao L, Merlo A, Bedi G, et al: A novel p16INK4A transcript. Cancer Res 55:2995-2997, 1995
33. Van Allen EM, Wagle N, Levy MA: Clinical analysis and interpretation of cancer genome data. J Clin Oncol 31:1825-1833, 2013
34. Sukhai MA, Craddock KJ, Thomas M, et al: A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet Med 18:128-136, 2016
35. Ritter DI, Roychowdhury S, Roy A, et al: Somatic cancer variant curation and harmonization through consensus minimum variant level data. Genome Med 8:117, 2016
36. Li MM, Datto M, Duncavage EJ, et al: Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn 19:4-23, 2017
37. Lek M, Karczewski KJ, Minikel EV, et al: Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285-291, 2016
38. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
39. Barras D: BRAF mutation in colorectal cancer: An update. Biomark Cancer 7:9-12, 2015 (suppl 1)
40. Koehler K, Liebner D, Chen JL: TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-543, 2016
41. Spigel DR, Edelman MJ, O’Byrne K, et al: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J Clin Oncol 35:412-420, 2017
42. Perry CA: Knowledge bases in medicine: A review. Bull Med Libr Assoc 78:271-282, 1990
43. Levesque HJ. The Logic of Knowledge Bases. Cambridge, MA: MIT Press, 2016
44. Landrum MJ, Lee JM, Benson M, et al: ClinVar: Public archive of interpretations of clinically relevant variants. Nucleic Acids Res 44:D862-D868, 2016 (suppl D1)
45. Rehm HL, Berg JS, Brooks LD, et al: ClinGen–the clinical genome resource. N Engl J Med 372: 2235-2242, 2015
46. Micheel CM, Lovly CM, Levy MA: My cancer genome. Cancer Genet 207:289, 2014
47. Griffith M, Spies NC, Krysiak K, et al: CIViC is a community knowledgebase for expert crowd-sourcing the clinical interpretation of variants in cancer. Nat Genet 49:170-174, 2017
48. Huang L, Fernandes H, Zia H, et al: The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations. J Am Med Inform Assoc 24:513-519, 2017
49. National Center for Biotechnology Information: All resources. https://www.ncbi.nlm.nih.gov/guide/all/
50. Federal Register: Use of public human genetic variant databases to support clinical validity for next generation sequencing-based in vitro diagnostics; Draft guidance for stakeholders and Food and Drug Administration Staff; Availability. https:// www.federalregister.gov/documents/2016/07/08/2016-16200/use-of-public-human-genetic-variant-databases-to-support-clinical-validity-for-next-generation
51. Rishel W: Sidecar EHR apps: SMART and FHIR lift vendors over the hump and on to new humps. http://rishel.com/blog/2017/04/ehrfhir-sidecarsover-the-hump-and-on-to-new-humps/
52. Collins FS, Varmus H: A new initiative on precision medicine. N Engl J Med 372:793-795, 2015
53. Hsu ER, Klemm JD, Kerlavage AR, et al: Cancer moonshot data and technology team: Enabling a national learning healthcare system for cancer to unleash the power of Data. Clin Pharmacol Ther 101:613-615, 2017
54. Sledge GW Jr, Miller RS, Hauser R: CancerLinQ and the future of cancer care. Am Soc Clin Oncol Educ Book 33:430-434, 2013